Please use this identifier to cite or link to this item:
https://doi.org/10.1038/s41375-020-0819-8
Title: | Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma | Authors: | Goldschmidt, Hartmut Dimopoulos, Meletios A Rajkumar, S Vincent Weisel, Katja C Moreau, Philippe Chng, Wee-Joo Mikala, Gabor Cavo, Michele Ramasamy, Karthik Suryanarayan, Kaveri Teng, Zhaoyang Labotka, Richard Victoria Mateos, Maria |
Keywords: | Science & Technology Life Sciences & Biomedicine Oncology Hematology STEM-CELL TRANSPLANTATION LENALIDOMIDE MAINTENANCE DOUBLE-BLIND THERAPY BORTEZOMIB |
Issue Date: | 23-Apr-2020 | Publisher: | SPRINGERNATURE | Citation: | Goldschmidt, Hartmut, Dimopoulos, Meletios A, Rajkumar, S Vincent, Weisel, Katja C, Moreau, Philippe, Chng, Wee-Joo, Mikala, Gabor, Cavo, Michele, Ramasamy, Karthik, Suryanarayan, Kaveri, Teng, Zhaoyang, Labotka, Richard, Victoria Mateos, Maria (2020-04-23). Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. LEUKEMIA 34 (11) : 3019-3027. ScholarBank@NUS Repository. https://doi.org/10.1038/s41375-020-0819-8 | Abstract: | In the TOURMALINE-MM3 study, post-autologous stem cell transplantation maintenance therapy with the oral proteasome inhibitor ixazomib versus placebo significantly improved progression-free survival (PFS), with a favorable safety profile. With ixazomib versus placebo maintenance, deepening responses occurred in 139/302 (46%) versus 60/187 (32%) patients with very good partial response or partial response (VGPR/PR) at study entry (relative risk 1.41, P = 0.004), and median time to best confirmed deepened response was 19.9 versus 30.8 months (24-month rate: 54.2 versus 41.4%; hazard ratio (HR): 1.384; P = 0.0342). Median PFS in patients with VGPR/PR at study entry was 26.2 versus 18.5 months (HR: 0.636, P < 0.001) with ixazomib versus placebo; in a pooled analysis across arms, in patients with versus without deepening responses, the median PFS was not reached versus 15.9 months (HR: 0.245, P < 0.001). In patients with deepening responses, 24-month PFS rate was 77.4 versus 68.3% with ixazomib versus placebo (HR: 0.831; P = 0.466); in patients without deepening responses, median PFS was 17.9 versus 14.1 months (HR: 0.741; P = 0.028). These analyses demonstrate the significantly higher rate of deepening responses with ixazomib versus placebo maintenance and the association between deepening response and prolonged PFS. | Source Title: | LEUKEMIA | URI: | https://scholarbank.nus.edu.sg/handle/10635/229005 | ISSN: | 08876924 14765551 |
DOI: | 10.1038/s41375-020-0819-8 |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant mainte.pdf | Published version | 644.85 kB | Adobe PDF | OPEN | Published | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.